drugset
drugset / Trial / NCT05147467

Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL

NCT05147467 ↗

Phase 2 Recruiting 75 enrolled Ascentage Pharma Group Inc.
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the efficacy and safety of APG-2575 single agent in patients with relapsed/refractory CLL/SLL.

Timeline

Start
2021-12-28
Primary completion
2026-12
Completion
2027-12

Drugs

EvaluationDrugModalityDoseRoute
Subject APG-2575 Small molecule 600 mg Oral

Indications

chronic lymphocytic leukemia/small lymphocytic lymphoma